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Research in context 52 
Evidence before this study 53 
Panretinal laser photocoagulation (PRP) is the standard of care for patients with 54 
proliferative diabetic retinopathy (PDR). Currently, 3 anti-vascular endothelial growth 55 
factor (anti-VEGF) therapeutic agents are administered by intravitreal injections to 56 
treat ophthalmic conditions. Bevacizumab and ranibizumab are monoclonal 57 
antibodies against VEGF A. Pre-CLARITY trial, we reviewed PubMed articles 58 
between January 1st 2005 and January 31st 2014 and there were 8 short-term 59 
randomised controlled trials (RCTs) comparing either bevacizumab or ranibizumab 60 
monotherapy or in combination with PRP versus PRP alone in high risk PDR. These 61 
RCTs showed new vessel regression with these agents after 3 to 4 months. 62 
Aflibercept is the latest anti-VEGF agent and it blocks all isomers of VEGF A, B, 63 
placental growth factor 1 and 2, and galectin-1. To date, there have been no RCTs on 64 
aflibercept in PDR.  65 
We updated the review on March 1st 2017. A well-designed multicentre clinical trial 66 
comparing ranibizumab monotherapy versus PRP in patients with high risk PDR, with 67 
and without macular oedema, has been published. Primary outcome of this RCT at 2 68 
years showed non-inferiority of ranibizumab versus PRP in high risk PDR with a 69 
median of 10 injections over 2 years (7 injections in the first year). However, this 70 
RCT has not changed clinical practice worldwide due to the perceived difficulties 71 
with practicalities of delivering repeated intravitreal injections in PDR patients and 72 
the study only showed non-inferiority of BCVA to PRP albeit beneficial secondary 73 
outcomes. Therefore, PRP remains the preferred choice.  74 
In addition, a substantial proportion of patients after initial PRP are under long-term 75 
follow-up in retinal clinics to identify and treat reactivation of existing 76 
neovascularisation with supplemental PRP and these patients have been excluded 77 
from previous clinical trials. Therefore, the role of anti-VEGF in this patient cohort 78 
remains unclear.   79 
 80 
Added value of this study 81 
The CLARITY study is the first RCT on intravitreal aflibercept in PDR and it 82 
provides substantial evidence that the visual outcome of active PDR at one year with 83 
aflibercept therapy is superior to PRP. This is also the first study to show a superior 84 
visual acuity outcome with an anti-VEGF agent in eyes with PDR with no baseline 85 
macular oedema. Furthermore this effect was achieved with 4 aflibercept injections (a 86 
median of 1 injection after the 3 loading doses in a year) irrespective of the PDR risk 87 
status and previous PRP treatment history, providing important evidence that 88 
aflibercept therapy can be adopted as an alternative to PRP in the first year of therapy. 89 
The study also showed a significantly lower incidence of macular oedema and 90 
vitreous haemorrhage and fewer adverse effects on binocular visual acuity and visual 91 
fields with aflibercept compared to PRP further highlighting the advantages of 92 
aflibercept over PRP with comparable systemic adverse effects. Most importantly, the 93 
patient satisfaction scores suggest patient preference for aflibercept therapy over PRP 94 
in a clinical trial setting.    95 
 96 
Interpretation 97 
In the first year of therapy, aflibercept is an effective treatment for active PDR and 98 
may be adopted as an alternative option to PRP.  99 
 100 
 101 
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Abstract 102 
 103 
Background: Proliferative diabetic retinopathy (PDR) is the most common cause of 104 
severe sight impairment in diabetes mellitus. PDR has been managed by pan-retinal 105 
laser photocoagulation (PRP) for the past 40 years. Here we report the 1-year safety 106 
and efficacy of intravitreal aflibercept.  107 
  108 
Methods:   109 
Adults with treatment naïve or post-laser treated active PDR from 22 UK ophthalmic 110 
centres were recruited to this phase 2b, non-inferiority trial and randomly assigned 111 
(1:1) to repeated intravitreal aflibercept or PRP standard care for 52 weeks. 112 
Randomisation was by minimization using a web-based computer generated system. 113 
Primary outcome assessors were masked optometrists. The treating ophthalmologists 114 
and participants were not masked. The primary outcome was defined as a change in 115 
best-corrected visual acuity (BCVA) at 52 weeks using a linear mixed-effects model 116 
that estimated adjusted treatment effects at both 12 and 52 weeks, having excluded 117 
fluctuations in BCVA owing to vitreous haemorrhage. This modified intention-to-118 
treat analysis was re-applied to the per protocol participants. The non-inferiority 119 
margin was pre-specified as -5 letters. Safety was assessed in all participants. Trial 120 
registration: ISRCTN32207582. 121 
  122 
Findings.  123 
We recruited 232 participants (116 per arm) between August 2014 and November 124 
2015. 221 participants (n=112 aflibercept arm, n=109 PRP arm) contributed to the 125 
modified intention-to-treat model, and 210 participants (n=104 aflibercept arm and 126 
n=106 PRP arm) within per protocol. Aflibercept was non-inferior and superior to 127 
PRP in both the modified intention-to-treat population (mean BCVA difference 3.9 128 
letters; 95% CI 2.3-5.6 letters; p<0.0001) and the per protocol population (difference 129 
4.0 letters; 95% CI 2.4 -5.7 letters, p<0.0001). There were no safety concerns.  130 
  131 
Interpretation. 132 
Intravitreal aflibercept in PDR results in improved outcome at 1 year compared to 133 
PRP standard care. 134 
  135 
Funding 136 
The Efficacy and Mechanism Evaluation Programme, a Medical Research Council 137 
and National Institute for Health Research partnership; Aflibercept was supplied by 138 
Bayer Plc, Reading, UK.  139 
 140 
 141 
 142 
 143 
 144 
 145 
 146 
 147 
 148 
 149 
 150 
 151 
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Clinical Efficacy of intravitreal aflibercept versus panretinal photocoagulation 152 
on best corrected visual acuity in patients with proliferative diabetic retinopathy 153 
at 52 weeks (CLARITY): a multicentre, single-blinded randomised, controlled 154 
phase IIb non-inferiority trial.  155 
 156 
Introduction 157 
 158 
Proliferative diabetic retinopathy (PDR) is the commonest cause of severe visual loss 159 
in people with diabetes.1 It is characterised by the growth of new abnormal vessels on 160 
the retina or optic disc that can result in sight threatening complications such as  161 
vitreous haemorrhage and tractional retinal detachment. 162 
 163 
Panretinal laser photocoagulation (PRP) has been the standard of care for this 164 
condition for over 40 years and reduces the risk of severe visual loss by 50%. 2  165 
Patients identified with active PDR are treated urgently to complete initial PRP and 166 
then reviewed regularly to identify and treat recurrent or de novo active 167 
neovascularisation with supplemental PRP. Repeated supplemental PRP is associated 168 
with permanent sequelae on visual function including final visual acuity below the 169 
driving standard, restricted visual fields that preclude driving, night vision difficulties, 170 
loss of colour vision and reduced contrast sensitivity and increased macular oedema.3-171 
7 Although laser technology and techniques have evolved over the last decade to 172 
reduce side-effects, 5, 6 approximately 4.5% progress to require vitrectomy surgery.8 173 
Therefore, there is a significant unmet need for novel treatments that reduce the risk 174 
of severe visual loss in PDR non-inferiority PRP with fewer side-effects.  175 
 176 
Ranibizumab and bevacizumab, monoclonal antibody inhibitors of vascular 177 
endothelial growth factor-A (VEGF-A), have been shown to cause short-term new 178 
vessel regression, either as monotherapy or in combination with PRP. 9 Since this 179 
study commenced, a randomised clinical trial comparing ranibizumab and PRP 180 
reported 2-year outcomes in high risk PDR with and without macular oedema and 181 
showed ranibizumab monotherapy is non-inferior to PRP, with less visual field loss 182 
and incident vitrectomy. 10 The latest anti-VEGF agent, aflibercept (Bayer Pharma 183 
AG, Berlin, Germany), is a recombinant fusion protein comprising the binding 184 
domains of VEGF-1 and -2 receptors, binds to VEGF with greater affinity than 185 
ranibizumab or bevacizumab and demonstrates activity against VEGF-A, -B, and 186 
placental growth factor. 11 This is the first study to evaluate efficacy and safety of 187 
intravitreal aflibercept in the management of PDR.  188 
 189 
Methods 190 
Study design and participants 191 
CLARITY is a multicentre, prospective, two-arm, parallel-group, randomised, non-192 
inferiority trial. Patients were recruited from 22 UK National Health Service 193 
hospitals.  194 
 195 
The study was granted approval by the National Research Ethics Committee Service 196 
London - South East (14/LO/0203). Clinical Trials Authorisation was given by the 197 
MHRA (11518/0013/001-0001) and the European Union Drug Regulating Authorities 198 
Clinical Trials (EudraCT) number was 2013-003272-12. Trial Steering and Data 199 
Monitoring Committees provided independent oversight.  200 
 201 
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Eligible patients with type 1 or 2 diabetes mellitus, aged 18 years or older, with clinical 202 
evidence of treatment naïve PDR or persistent retinal neovascularization following 203 
initial PRP requiring additional PRP (i.e. non treatment naïve) were included. Best 204 
corrected visual acuity (BCVA) was ≥54 Early Treatment Diabetic Retinopathy Study 205 
(ETDRS) letters, equivalent to 6/24 Snellen BCVA with sufficient media clarity and 206 
pupillary dilatation for adequate fundus photographs. The fellow eye Snellen BCVA 207 
was ≥ 2/60. Women patients were using effective contraception, post-menopausal for ≥ 208 
12 months prior to trial entry, or surgically sterile. Study eye exclusion criteria were co-209 
existent ocular disease that affected or may affect visual acuity or prevent treatment 210 
delivery. As diabetic macular oedema can co-exist with PDR and confound visual 211 
acuity outcomes, all eyes with clinical evidence of diabetic macular oedema and 212 
spectral domain optical coherence tomography central subfield thickness ≥ 300µm due 213 
to macular oedema were excluded. Other ocular exclusions were moderate or dense 214 
vitreous haemorrhage preventing clear visualisation of the macula and/or optic disc or 215 
preventing laser treatment, fibrovascular proliferation or tractional retinal detachment 216 
in the posterior pole, prior vitrectomy, other causes of retinal neovascularization, and 217 
anticipated need for cataract extraction or vitrectomy within 12 months. Patients treated 218 
with intravitreal anti-VEGF or steroid for DMO within 4 months or PRP within 8 weeks 219 
prior to screening were excluded. Systemic exclusion criteria included haemoglobin 220 
A1c (HbA1c) ≥12%, blood pressure ≥170/110 mmHg and any medical condition that, 221 
in the opinion of the investigator, precluded participation in the study. The clinical 222 
assessments schedule is detailed in table S1 and S2, appendix and in the published 223 
protocol.12 224 
 225 
Randomisation and masking 226 
Patients provided informed consent and those eligible were randomly allocated (1:1) 227 
to either repeated intravitreal aflibercept 2mg/0.05ml (Bayer Pharma AG) or PRP 228 
using the method of minimisation, concealed before allocation, stratified by site, 229 
baseline PDR status (naïve versus non-naïve), BCVA (54-69 versus ≥70 ETDRS 230 
letters), HbA1c (<8% [<63.89mmol/l], ≥8% to ≤10% [63.90 to 85.8mmol/mol] and 231 
>10% [>85.81mmol/mol], diastolic blood pressure (≤90mmHg versus >90mmHg) by 232 
collaborating site investigators via the King’s Clinical Trials Unit web-based 233 
randomisation service. Patients and clinical investigators were unmasked due to the 234 
anatomical changes induced by the comparator. Outcome assessors including 235 
optometrists, visual field technicians, imaging technicians and the Independent 236 
Reading Centre were masked to treatment allocation. Primary outcome assessors 237 
completed a treatment guess form to determine masking success. 238 
 239 
 240 
Procedures 241 
The intervention arm received intravitreal aflibercept injections (Bayer Pharma AG). 242 
The dose of each intravitreal aflibercept injection was 2 mg/0.05ml and patients 243 
received mandated injections at baseline, 4 and 8 weeks. From week 12, patients were 244 
reviewed every four weeks and aflibercept injections were given pro-re-nata based on 245 
the degree of regression and reactivation of neovascularisation of disc and elsewhere 246 
observed on clinical examination with adequate visualisation of entire retina and 247 
compared to 7-field colour photographs or wide-field photography at screening or 248 
previous visit. Patients were categorised into 3 groups according to treatment response 249 
into no regression, partial regression and total regression as shown in table S3, 250 
appendix. Treatment was deferred at the investigator’s discretion where eyes had 251 
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experienced adverse events such as vitreous haemorrhage, retinal detachment or raised 252 
intraocular pressure ˃30mmHg. If aflibercept became contraindicated during the trial 253 
(e.g. newly pregnant woman), patients were treated with PRP. The comparator arm 254 
received standard PRP treatment delivered as per routine clinical practice by direct, 255 
single or multispot or indirect means targeting areas of non-perfusion initially. Patients 256 
in the PRP arm had PRP at baseline and in fractionated fortnightly sessions thereafter, 257 
with follow-up at week 12. From week 12, PRP arm patients were assessed for 258 
treatment response every 8 weeks and regression patterns categorised exactly as the 259 
aflibercept arm. Treatment in the PRP arm was deferred if the media was too hazy or if 260 
the investigator judged that the eye had receive adequate PRP. 261 
 262 
BCVA was measured at 4 metres using validated ETDRS visual acuity charts 263 
employing standard operating procedures for studies in diabetic retinopathy. Refracted 264 
visual acuity was done at screening, 12 and 52 weeks and withdrawal. Secondary 265 
outcomes included Pelli Robson contrast sensitivity letter scores, uniocular and 266 
binocular percentages Esterman driving visual field efficiency score (missed spots), 267 
colour fundus photography, OCT and fundus fluorescein angiography. Patient related 268 
outcomes were measured using validated questionnaires at screening and 52 weeks. 269 
These included National Eye Institute -Vision-Related Quality of Life (NEI-VFQ 25), 270 
a diabetic retinopathy specific quality of life questionnaire (RetDQoL) and diabetic 271 
retinopathy treatment satisfaction questionnaire (RetTSQ). Health-related quality of 272 
life, activity scales and health and social care service use will be reported in a 273 
subsequent cost-effectiveness paper. A subset of patients (n=40) also underwent 274 
oximetry and this mechanistic component of the study will be reported later.  275 
 276 
Outcomes 277 
The primary outcome was BCVA letter change from baseline to 52 weeks in study eye 278 
in the aflibercept arm relative to the PRP arm. A secondary outcome was BCVA change 279 
from baseline to 12 weeks. Additional secondary visual function outcomes assessed at 280 
52 weeks included uniocular and binocular Esterman missed spots, binocular visual 281 
acuity letter scores, low luminance visual acuity letter scores, categories of visual 282 
acuity outcomes in terms of visual gain or loss, and contrast sensitivity letter scores. 283 
Change from baseline between arms in patient reported outcomes using NEI-VFQ-25, 284 
RetDQol, RetTSQ at 52 weeks. Anatomical outcomes included new vessel regression 285 
patterns and change in ETDRS diabetic retinopathy severity score levels at 12 and 52 286 
weeks (table S4, appendix). 13 The number of treatments required in both arms and 287 
the proportion of patients requiring supplemental PRP in the aflibercept arm were 288 
reported. We evaluated differences in ocular and systemic safety profile between arms 289 
from baseline to 52 weeks.  290 
Adverse events were recorded per visit, site investigators determined relatedness and 291 
Chief Investigator determined expectedness of all serious adverse events. Adverse 292 
events were coded by two masked clinicians.  293 
 294 
Statistical analysis 295 
The intention-to-treat population was defined to comprise all randomised patients. 296 
The per protocol population was defined to exclude those randomised patients found 297 
to be ineligible at entry, and those not receiving the full randomised treatment up to 298 
and including the 8-week visit (whether due to discontinuation, exclusion or other 299 
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reason for missing a randomised treatment in this period). A statistical analysis plan 300 
was finalised before data lock and agreed with oversight committees. The primary 301 
outcome of refracted BCVA was compared between arms primarily at the 52-week 302 
point and secondarily at the 12-week point using a linear mixed effects model with 303 
patient as a random effect to allow for within-patient correlation of repeated measures 304 
over time. Fixed effects included the main effects and interactions with “time” (12 305 
and 52 weeks) for treatment arm, the minimisation stratifiers: PDR status, contrasts 306 
for HbA1c, blood pressure, the baseline of the outcome and its missing indicator 307 
required for the missing indicator method. 14As pre-specified, any BCVA 308 
measurement at 12 and 52 weeks which was both >3SD below the mean at that time 309 
point (including all measurements) and recorded within 3 months of the occurrence of 310 
a vitreous haemorrhage was excluded from analysis to avoid erroneous influence on 311 
the statistical analysis. Some sites recruited a very small number of patients and so 312 
study site was not included in models to allow these patients to contribute to 313 
estimating treatment effects rather than site effects. The test for non-inferiority was 314 
one-sided at the 2.5% significance level, and is presented as an estimated effect with 315 
two-sided 95% confidence interval compared against the non-inferiority margin of -5 316 
letters. For the analysis of the primary outcome, the mixed effects model was re-fitted 317 
within the per protocol population. Analyses were completed according to the 318 
intention-to-treat strategy with intention-to-treat and per protocol analyses modified 319 
for missing and excluded data together with principled sensitivity analysis in the full 320 
intention-to-treat and per protocol populations.15, 16 Secondary continuous outcomes 321 
were analysed only on the intention-to-treat basis modified for omitted data and with 322 
the same model specification as for the primary outcome, and reported as adjusted 323 
differences in means.  All tests were two-sided at the 5% significance level and effect 324 
sizes interpreted cautiously with 95% confidence intervals. Safety and other 325 
categorical outcomes are reported as proportions with 95% confidence intervals and 326 
Pearson's chi-squared tests, or Fisher’s exact tests and Wilson's exact confidence 327 
intervals when any expected table counts were smaller than five.  328 
 329 
Sensitivity to the missing at random assumption made in the primary outcome analysis 330 
was undertaken in all randomised patients to assess sensitivity to the handling of 331 
missing and excluded 52-week data, using three recommended scenarios affecting 332 
either one or both arms.16 Sensitivity analysis was used to assess the use of concomitant 333 
treatments, to assess changes to conclusions from inclusion of isolated outliers in 334 
statistical analyses defined as exceeding four standard deviations from expected, and to 335 
assess additional adjustment for all sites as a fixed effect.  336 
 337 
Pre-planned subgroup analyses for primary outcomes were done by extending the 338 
models to include interaction terms with arm for the randomisation stratifiers 339 
including baseline visual acuity, HbA1c, diastolic BP and PDR status (naïve and non-340 
naïve).  341 
 342 
The planned sample size was 220 participants. Detailed sample size calculations are 343 
available in the published protocol. The SD of the change in visual acuity, after 344 
adjustment for baseline, was anticipated to be 10.3, based on the estimate from a 345 
relevant trial.17 In brief, the study had at least 90% power to detect non-inferiority of -346 
5 letters using a two-sided 95% confidence interval from an analysis of covariance 347 
test with adjustment for baseline visual acuity.12, 16  348 
Role of the funding source 349 
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Neither the funders nor the provider of active medication had any role in study design, 350 
patient recruitment, data collection, data analysis, data interpretation, writing or 351 
editing the report or the decision to submit for publication. The statisticians had full 352 
access to all data in CLARITY and the Chief Investigator had final responsibility for 353 
the decision to submit for publication.  354 
 355 
Results 356 
Between August, 2014, and December, 2015, 290 patients were assessed for 357 
eligibility and 232 randomly assigned to receive intravitreal aflibercept (n=116) or 358 
PRP (n=116) (figure 1).  359 
 360 
Baseline characteristics were well balanced between treatment groups (table 1). A total 361 
of 123 (53%) treatment naïve and 109 (47%) non-naïve patients were recruited. Mean 362 
baseline BCVA was 81·4 (SD 8·1) ETDRS letters. The proportion of patients with 363 
baseline BCVA 54-69 and ≥70 ETDRS letters were 9% and 91% respectively. 364 
 365 
Derivation of the Intention- to-treat model and Per-protocol populations 366 
Patients included in the pre-specified Intention-to-Treat linear mixed effect model 367 
were derived as follows: (1) The BCVA data were available for 211 patients of 232 368 
randomly assigned patients (107 in aflibercept and 104 in PRP arms) at 52 weeks and 369 
for 214 patients at 12-weeks (109 in aflibercept and 105 in PRP arm); (2) A total of 4 370 
patients in the PRP arm at 12 weeks and 2 patients in the aflibercept arm at 52 weeks 371 
were excluded due to presence of vitreous haemorrhage within 3 months of BCVA 372 
recordings and BCVA was more than 3SD below the mean at that time point 373 
(including all measurements); (3) There were 198 patients with BCVA available at 374 
both 12 and 52 weeks. A total of 11 patients had BCVA recorded at 52 weeks and not 375 
12 weeks (8 in PRP arm and 3 in aflibercept arm). In addition, there were 12 patients 376 
who had BCVA recorded at 12 weeks but not at 52 weeks (5 in PRP and 7 in 377 
aflibercept arm); (4) Therefore, there were 221 patients that contributed to the 378 
analysis in the linear mixed effect model for the intention-to-treat strategy (109 in the 379 
PRP arm and 112 in the aflibercept arm); (5) A total of 18 patients did not meet the 380 
PP definition and were not included in the PP population (n=214). This included 11 381 
(9·5%) patients in the aflibercept arm and 7 (6·0%) in the PRP arm), with 4 patients 382 
in the aflibercept arm and 4 in the PRP arm not being compliant with the eligibility 383 
criteria and a further 7 patients in the aflibercept arm and 3 in the PRP who did not 384 
receive initial mandatory treatment requirements. Therefore, there were 210 patients 385 
that contributed to the PP analysis in the LME model (106 in the PRP arm and104 in 386 
the aflibercept arm).  387 
 388 
Primary outcome  389 
Primary outcome at 52 weeks showed aflibercept was superior to PRP in terms of 390 
BCVA in both intention-to-treat and per-protocol populations (table 2). Adjusted 391 
difference between arms fell above the pre-specified acceptable margin of -5 letters 392 
for the 95% CI at both 12 and 52 weeks.  393 
Three sensitivity analyses on the population with completed follow-up at 52 weeks 394 
were done, adjusting for sites, outliers and missing data. No patients were offered 395 
anti-VEGF treatment for macular oedema in the PRP arm. So sensitivity analysis for 396 
concomitant treatments was not required. When sites were considered, the adjusted 397 
difference in BCVA between arms remained significant at 4·1 letters (95% CI 2·4 to 398 
5·7), p<0·0001, and 4·1 letters (95% CI 2·4 to 5·7), p<0·0001, respectively in the 399 
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modified intention-to-treat and per protocol populations. A total of 207 and 198 400 
patients remained after outliers in the modified intention-to-treat and per protocol 401 
populations, defined as less than or more than 4SD were removed. This sensitivity 402 
analysis showed the adjusted difference in BCVA between arms as significant at 4·0 403 
letters (95% CI 2·7 to 5·4, p<0·0001) in the modified intention-to-treat and 4·1 letters 404 
(95% CI 2·7 to 5·5, p<0·0001) in the per protocol population.  The sensitivity 405 
analysis for missing data also confirmed a superiority effect in both intention-to-treat 406 
(n=232) and per protocol populations (n=214) for three pre-specified alternative 407 
scenarios (figure 2, appendix). 408 
 409 
Primary outcomes in treatment naïve and non-naïve groups are shown in table S5.  410 
  411 
Secondary outcomes 412 
Table S6 shows visual acuity in each stratum of visual acuity ranges at 52 weeks.  413 
 414 
The proportion of patients with greater or equal to 10 letter improvement and able to 415 
do so with baseline BCVA ≤90 was 5% (5/101) in the aflibercept arm compared to 416 
2% (2/95) in the PRP arm (difference between arms was 2·8% (95% CI -3.1% to 417 
9.1%, p=0·45). The proportion of patients with greater or equal to 10 letter worsening 418 
was 5% (5/107) in the aflibercept arm compared to 15% (16/104) in the PRP arm 419 
(difference between arms was 10·7%, 95% CI 2·6% to 19·3%, p=0·009). There were 420 
5% (5/107) of patients with greater or equal to 15 letter worsening in the aflibercept 421 
arm and 6% (6/104) in the laser arm (difference between arms was 1·1%, 95% CI (-422 
5.5% to 7.9%), p=0·72). 423 
 424 
Binocular Esterman scores showed significant worsening with the PRP arm. This was 425 
also reflected in lower binocular visual acuity scores in the PRP arm (Table S7). 426 
Other visual function tests did not vary between arms. Table S8 shows changes in 427 
visual function in treatment naïve and non-naïve cohorts.  428 
 429 
The RetDQoL scores (table S9) and NEI-VFQ scores (table S10) did not show 430 
significant differences between arms. RetTSQ scores showed that patient satisfaction 431 
scores were significantly better in the aflibercept arm and the adjusted mean 432 
difference was 3·0 (95% CI 0·4 to 5·5, p=0·022) (table S9). 433 
 434 
Anatomical outcomes 435 
Macular thickness and volume significantly increased in the PRP arm compared to the 436 
aflibercept arm (table S11). The proportion of patients with new onset centre-437 
involving macular oedema also increased significantly in the PRP arm (table S12). 438 
 439 
Treating investigators determined regression and reactivation patterns of retinal new 440 
vessels to decide re-treatment based on pre-defined criteria. Table S13 shows that a 441 
significant proportion of eyes showed total regression of retinal new vessels in the 442 
aflibercept arm compared to the PRP arm. The difference in proportions of total 443 
regression favouring the aflibercept arm was 30% (95% CI 16% to 42%), p<0·0001 at 444 
52 weeks. 445 
 446 
The UK Network of Reading Centres (Networc UK), masked to treatment allocation, 447 
graded ETDRS diabetic retinopathy severity scores from colour fundus photographs 448 
obtained at baseline, 12 and 52 weeks.13 Of patients with gradable photographs 449 
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(n=227), 175 (77%) were graded low risk PDR (Levels 61 and 65) and 52 (23%) high 450 
risk PDR (Levels 71 and 75). Three eyes were graded below level 61 (table S14). 451 
Improvement from diabetic retinopathy severity score is difficult to assess in lasered 452 
eyes and so the improvement of the level of remaining retinopathy was graded. 453 
Change in diabetic retinopathy severity level in treatment naïve eyes treated with 454 
aflibercept is also reported in table S15. A significantly higher proportion of patients 455 
in the PRP arm remained at PDR (level 61 or above) compared to the aflibercept arm 456 
at both 12 and 52 weeks.  457 
 458 
Treatment outcomes  459 
The proportion of patients that received treatment according to protocol was 94% 460 
(109/116) in the aflibercept arm and 97% (113/116) in the PRP arm. The treatment 461 
allocation guess form, measuring success of masking of primary assessors to 462 
treatment allocation, was reported for 210 participants. Assessors guessed correctly 463 
for 15% (32/210), incorrectly for 10% (20/210), and were unable to tell for 75% 464 
(158/210) of participants. 465 
 466 
By 52 weeks, aflibercept arm patients received a mean (SD) of 4·4 (1·7) injections, 467 
(95% CI 4·1 to 4·7), [Median (IQR) 4.0 (3.0 to 5.0)] including the 3 mandated 468 
loading doses. The mean number of aflibercept injections in treatment naïve patients 469 
was 4·6 (1·6) [Median (IQR) 4 (3, 6)] while non-naïve patients received a mean 470 
number of injections 4·1 (1·8), [Median (IQR) 4·0 (3·0 to 4·8)]. A total of 2 (1·6%) 471 
patients required supplemental PRP in the aflibercept arm.  472 
 473 
In the PRP arm, 78 (69%) received multispot laser and the remaining received single 474 
spot laser. The type of laser delivery was not recorded for 3 patients. Distribution of 475 
PRP session numbers required were 1 session in 35 eyes (30·2%); 2 sessions in 25 476 
eyes (21·6%), 3 sessions in 10 eyes (8·6%), 4 sessions in 4 eyes (3·4%) and 5 477 
sessions in 1 eye (0·9%). From week 12, 75 patients (65%) in the PRP arm required 478 
supplemental PRP. The mean number (SD) of supplemental PRP sessions required 479 
was 1·17 (1·16), 95% CI (0·96 to 1·38) with the treatment naïve patients requiring 480 
1·35 (1·28) sessions and in the non-naïve arm, the mean was 0·96 (0·96).   481 
 482 
Safety outcomes 483 
When comparing other complications of PDR between arms, incidence of vitreous 484 
haemorrhage was higher in the PRP arm (p=0.034). The proportion of patients 485 
requiring vitrectomy was small and not significant between arms (p=0·066). There 486 
were no cases of endophthalmitis in the study eye (table 3).  487 
 488 
Ocular adverse events in the non-study eye are shown in table S16. The number of 489 
vitreous haemorrhages in the non-study eye was recorded, as this complication may 490 
confound both the vision–related and health-related quality of life assessments.  491 
The Anti-Platelet Trialists` Collaboration (APTC) defined events showed no 492 
significant difference between arms (table 4). 18 Frequency of systemic adverse events 493 
did not differ between treatment arms (table S17).   494 
 495 
Discussion 496 
The results of this phase IIb trial demonstrate that intravitreal aflibercept monotherapy 497 
is superior to standard PRP treatment for PDR through 52 weeks. This is the first 498 
study to show that an anti-VEGF therapy can provide superior BCVA outcomes in 499 
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eyes with active PDR without baseline centre-involving macular oedema. Mean 500 
difference in BCVA letter score between arms in favour of aflibercept was small but 501 
significant, and was achieved with a median of one aflibercept injection only in the 40 502 
weeks post loading phase, indicating that aflibercept is a feasible new approach for 503 
compliant patients.  504 
 505 
Superior treatment satisfaction scores in the aflibercept arm were unexpected but 506 
highlighted patients’ preference for this therapy. The lower incidence of centre-507 
involving macular oedema and vitreous haemorrhage observed in the aflibercept arm 508 
may have contributed to both the mean BCVA improvement and patient preference as 509 
these conditions are the most common causes of symptomatic visual impairment in 510 
patients with PDR. The proportion of patients with no macular oedema at 52 weeks 511 
was 89% (93/105) in the aflibercept arm compared to 71% (74/104) in the PRP arm. 512 
The incidence of vitreous haemorrhage was twice as high in the PRP arm (18% 513 
(21/116) compared to 9% (10/116) in the aflibercept arm).  514 
 515 
Other factors that may explain the superior effect of aflibercept may include a high 516 
aflibercept VEGF binding affinity and blockade of other angiogenic pathways such as 517 
placental growth factor and galectin-1.19, 20 However, the exact mechanisms of these 518 
pathways in PDR remain to be understood.  519 
 520 
The superior BCVA findings were supported by significantly better binocular visual 521 
acuity and binocular Esterman scores in the aflibercept arm. These observations have 522 
significant impact on eligibility to retain a driving licence. In the UK, the Driver and 523 
Vehicle Licensing Agency (DVLA) have designated both a minimum visual acuity 524 
and Esterman visual field standard to maintain a valid driving licence. 21 With 525 
advances in laser technology and techniques, there are reports with short follow-up 526 
suggesting that modern-day laser techniques and technology such as multispot laser 527 
have reduced the prevalence of visual field loss with PRP.6, 21, 22 However, our study 528 
shows that despite 69% of the study cohort being treated with multispot laser, 529 
aflibercept is associated with lower risk of visual field loss than modern day laser at 530 
52 weeks, in keeping with findings noted in the recent ranibizumab trial in PDR at 2 531 
years.10  532 
Other visual outcomes that measured adverse effects of PRP such as contrast 533 
sensitivity and low luminance visual acuity were not significantly different between 534 
arms, although removing outliers suggested greater preservation of low luminance 535 
visual acuity letter score by 52 weeks in the aflibercept arm.  536 
Despite the good visual outcomes observed with this intervention with a median of 537 
only 4 injections in the first year, the acceptance rate amongst clinicians may vary 538 
because PRP is perceived to have a permanent effect and require fewer follow-up 539 
visits than anti-VEGF therapy. However, our study demonstrates that 65% of the 540 
patients in the PRP arm required supplemental PRP when monitored every 8 weeks 541 
over 52 weeks. The ranibizumab study also reported that 45% of the patients in the 542 
PRP arm required additional sessions by the end of two years.10 More importantly, 543 
loss of visual acuity of 10 or more letters was five times more common with PRP than 544 
aflibercept.  545 
The disease modifying effect of aflibercept is well established from diabetic macular 546 
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oedema trials, where aflibercept improves the level of diabetic retinopathy severity, 547 
alongside its effect on diabetic macular oedema.23 This anatomical effect should also 548 
be considered when choosing between anti-VEGF and PRP as a first line option in 549 
PDR. As aflibercept is licensed for diabetic macular oedema, the findings of this 550 
study indicate that aflibercept is also effective in the management of PDR in the first 551 
year, allowing the use of a single agent to address both of these sight-threatening 552 
complications of diabetes.  553 
 554 
The robust RCT design, high statistical power and excellent retention rates are 555 
particular strengths of this study. The study patients are representative of PDR 556 
population, therefore these findings can be generalised to clinical practice for the first 557 
year of therapy. Re-treatment criteria used in CLARITY are very similar to those 558 
followed in the ranibizumab trial10 and determined by treating investigators at each 559 
study visit. Compliance with treatment (94% aflibercept arm and 97% PRP arm) was 560 
very good in CLARITY, indicating that these re-treatment criteria can be easily 561 
applied to routine clinical practice.  562 
 563 
The safety evaluation of aflibercept in CLARITY revealed no new concerns. There 564 
were no differences in APTC events or other systemic adverse events between arms. 565 
 566 
The limitation of this study is that it was a Phase IIb study with follow-up for only 52 567 
weeks. To date, the only other well-designed study on anti-VEGF for PDR included 568 
patients with diabetic macular oedema and so the treatment regimen was pre-planned 569 
to be more intense than this study.10 However, as a 5 year study, it will provide long-570 
term outcomes of ranibizumab in PDR, information on the disease modifying effect of 571 
anti-VEGF and the long-term compliance of patients.  572 
 573 
In conclusion, this is the second study to show non-inferiority of anti-VEGF to PRP 574 
and the first study to show potential advantage in BCVA versus PRP with an anti-575 
VEGF agent, in this case aflibercept. The study also shows that patients prefer anti-576 
VEGF to PRP in a clinical trial setting. However, longer-term studies are required to 577 
evaluate long-term patient compliance and the disease modifying effect of different 578 
anti-VEGF agents in PDR both in Phase 3 clinical trials and in real-life setting. 579 
 580 
 581 
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